Amplyx Pharmaceuticals Is A Clinical Stage Biopharmaceutical Company Focused On Developing Therapies For Serious Diseasesparticularly Those Affecting Individuals With Compromised Immune Systemsacquired By Pfizer Incin April 2021Amplyx S Work Aligns With Pfizer S Commitment To Addressing Urgent Medical Needsespecially In The Area Of Infectious Diseases The Company Has Developed Several Promising Compoundsincluding Fosmanogepixapx001 An Investigational Antifungal Treatment Aimed At Invasive Fungal Infectionsother Compounds In Its Pipeline Include Mau868An Early Stage Antiviral Treatmentand Apx2039Another Antifungal Candidateas A Subsidiary Of Pfizeramplyx S Products Are Integrated Into Pfizer S Hospital Focused Business Unitserving Healthcare Providers And Patients In Need Of Effective Treatments For Severe Infections
